Background: Patients treated with immune checkpoint inhibitors (ICIs) may develop ICI-associated enterocolitis, for which there is no approved treatment.

Aims: We aimed to systematically review the efficacy and safety of medical interventions for the prevention and treatment of ICI-associated enterocolitis.


Checkpoint inhibitor, Cytotoxic T lymphocyte-associated protein, Infliximab, Ipilimumab, therapeutic use, immunotherapy, Immunosuppressive Agents, Enterocolitis, Adverse Effects

Read More